Ultram and Nephrogenic systemic fibrosis - a phase IV clinical study of FDA data

Summary:

Nephrogenic systemic fibrosis is reported as a side effect among people who take Ultram (tramadol hydrochloride), especially for people who are male, 40-49 old, have been taking the drug for 1 - 2 years also take Omniscan, and have Deep venous thrombosis.

The phase IV clinical study analyzes which people have Nephrogenic systemic fibrosis when taking Ultram. It is created by eHealthMe based on reports of 26,802 people who have side effects when taking Ultram from the FDA, and is updated regularly.

What is Ultram?

Ultram has active ingredients of tramadol hydrochloride. It is often used in pain. eHealthMe is studying from 28,425 Ultram users. Check the latest studies of Ultram.

What is Nephrogenic systemic fibrosis?

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease) is found to be associated with 505 drugs and 673 conditions by eHealthMe. Check the latest studies of Nephrogenic systemic fibrosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

26,802 people reported to have side effects when taking Ultram.
Among them, 13 people (0.05%) have Nephrogenic systemic fibrosis.

Could Ultram cause Nephrogenic systemic fibrosis?

Among these 13 people:

How long have people been on Ultram when they have Nephrogenic systemic fibrosis? *

What is the gender of people who have Nephrogenic systemic fibrosis when taking Ultram? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Nephrogenic systemic fibrosis when taking Ultram? *

What are other drugs people take besides Ultram? *

What are other side effects people have besides Nephrogenic systemic fibrosis? *

Skin Induration (an abnormally hard spot or area on the skin): 8 people, 61.54%
Mobility Decreased (ability to move is reduced): 7 people, 53.85%
Joint Pain: 7 people, 53.85%
Skin Hypertrophy (skin cells enlarges): 7 people, 53.85%
Scar: 6 people, 46.15%
Oedema Peripheral (superficial swelling): 6 people, 46.15%
General Physical Health Deterioration (weak health status): 6 people, 46.15%
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue): 6 people, 46.15%
Rashes (redness): 6 people, 46.15%
Pain In Extremity: 5 people, 38.46%

What are the existing conditions these people have? *

Radiculopathy (a set of conditions in which one or more nerves is affected and does not work properly): 2 people, 15.38%
Nuclear Magnetic Resonance Imaging Brain: 2 people, 15.38%
Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 15.38%
Urticaria (rash of round, red welts on the skin that itch intensely): 1 person, 7.69%
Dizziness: 1 person, 7.69%
Acute Kidney Failure: 1 person, 7.69%
Anaemia (lack of blood): 1 person, 7.69%
Blood Pressure Abnormal: 1 person, 7.69%
Brain Neoplasm (tumour of brain): 1 person, 7.69%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Ultram and have Nephrogenic systemic fibrosis?

- Check whether Nephrogenic systemic fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ultram:

Ultram (28,425 reports)

Browse all side effects of Ultram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (505 drugs)

Browse all the conditions that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (673 conditions)

Related publications that referenced our studies

Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .
Mansour HM, "Tramadol and Disseminated Intravascular Coagulopathy: A Case Report", Medicine Science, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on tramadol hydrochloride (the active ingredients of Ultram) and Ultram (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.